Vita 34 AG: Vita 34 starts successful into 2016; Total Operating Revenue up by 16.3 percent

DGAP-News: Vita 34 AG / Key word(s): Quarterly / Interim Statement

2016-05-25 / 10:10
The issuer is solely responsible for the content of this announcement.

Vita 34 starts successful into 2016; Total Operating Revenue up by 16.3 percent

– Total operating revenue increased by 16.3 percent to EUR 4.0 million

– Expansion of corporate activities in promising growth markets in the Middle East

Leipzig, May 25, 2016 – In the first three months of 2016, Vita 34 increased total operating income as compared with last year by 16.3 percent to EUR 4.0 million (Q1 2015: EUR 3.4 million). Sales revenues increased by 24.2 percent to a total of EUR 3.8 million (Q1 2015: EUR 3.1 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) were EUR 0.3 million (Q1 2015: EUR 0.6 million). This is equivalent to an EBITDA margin of 8.3 percent (Q1 2015: 19.9 percent). This results in a profit per share of EUR 0.01 in Q1 2016 based on an average number of issued shares of 3,026,500 (Q1 2015: EUR 0.09).

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented on the development of the company’s business: “Vita 34 has had a successful start in fiscal year 2016. We have advanced the integration of subsidiaries, especially StemCare ApS. Of course, in the short term the integration process is associated with higher costs, which also puts downward pressure on margins. In the medium-term, however, we will increase efficiencies, as well as our profitability.”

Vita 34 entered into new cooperation agreements with partners in Dubai and Lebanon in the first quarter. Within the context of the partnership, Vita 34 is assuming the tasks of processing, testing, and cryo-preservation of umbilical cord blood and tissue. The partner companies are responsible for marketing and sales, training the clinics, collection, as well as transport of the preparations to Leipzig.

Dr. André Gerth: “Sales and marketing partnerships are an important compliment to our Buy and Build strategy. Through them we secure our position as the undisputed market leader in the German-speaking countries, and at the same time create a solid foundation for increasing out market share in foreign markets. Apart from new markets, we also want to grow by means of innovative products and new applications. Therefore, we are continuously investing in research and development activities.”

Stem cells from cord blood can perspectively supplement today’s established therapies for treatment of cartilage damage, tendon and sport injuries as well as arthritis, to some extend even replace them. Vita 34 offers the chance to secure this potential. Unfortunately many people do not have this opportunity to revert to their own cord blood. Therefore Vita 34 is researching the potential of other stem cell sources and will develop applicable products.

The complete quarterly report for the first three months of 2016 is available immediately for download on the Internet at in the Investor Relations section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 145,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.

2016-05-25 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this